Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry

Status Completed

Clinical Trial Summary

Venous thromboembolic disease is a significant cause of morbidity and mortality. The purpose of the RAPID registry is to collect information on the Angiovac procedure and Angiovac device used in the treatment of deep venous thrombosis (DVT), right heart pathology and pulmonary embolism.

Clinical Trial Description

Venous thromboembolic disease is a significant cause of morbidity and mortality. Thrombolytic therapy has been shown to be a successful treatment modality, however its use is somewhat limited due to the known risk of hemorrhage (overall 22%, with up to 3% intracranial hemorrhage), and suggested risk of distal embolization where large mobile thrombi are encountered. In patients where either thrombolysis is contraindicated or unsuccessful and conventional therapies inadequate, bulk thrombectomy may be considered. Until recently this was primarily achieved with surgical thrombectomy; however the Angiovac device is posited to offer a minimally invasive alternative.

This registry will collect data on patients in whom the Angiovac device was placed into the body for management of inferior vena cava (IVC) clots, right atrial (RA) masses or pulmonary emboli (PE) will be included.

This registry is to capture high quality patient safety and effectiveness data on use of the Angiovac device for 3 separate, but overlapping conditions; a) Iliofemoral and Caval DVT, b) Right heart masses, and c) PE. The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the angiovac catheter deployed into the vascular system.

Any center performing Angiovac procedure and wishing to contribute patient data will be offered participation in the registry. These core sites will be required to submit the registry protocol for Institutional Review Board (IRB) review. Once documentation of IRB approval has been received, centers may transmit their data via secure REDCap (Research Electronic Data Capture) database in accordance with federal regulations in the Health Insurance Portability and Accountability Act (HIPAA ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04414332
Study type	Observational [Patient Registry]
Source	University of California, Los Angeles
Contact
Status	Completed
Phase
Start date	September 1, 2015
Completion date	February 27, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05050617` - Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
Terminated	`NCT04558125` - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism	Phase 4
Not yet recruiting	`NCT06017271` - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Completed	`NCT03915925` - Short-term Clinical Deterioration After Acute Pulmonary Embolism
Completed	`NCT02502396` - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Recruiting	`NCT05171075` - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE	Phase 3
Completed	`NCT04454554` - Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
Completed	`NCT03173066` - Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography	Phase 1
Terminated	`NCT03002467` - Impact Analysis of Prognostic Stratification for Pulmonary Embolism	N/A
Completed	`NCT02334007` - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery	Phase 1/Phase 2
Completed	`NCT02611115` - Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.	N/A
Completed	`NCT01975090` - The SENTRY Clinical Study	N/A
Not yet recruiting	`NCT01357941` - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)	N/A
Completed	`NCT01326507` - Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism	N/A
Completed	`NCT00720915` - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months	N/A
Completed	`NCT00780767` - Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism	Phase 2
Completed	`NCT00771303` - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed	`NCT00773448` - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism	N/A
Completed	`NCT02476526` - Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease	Phase 4
Completed	`NCT00244725` - Odiparcil For The Prevention Of Venous Thromboembolism	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry — RAPID

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms